Drug · CHEMBL159

VINBLASTINE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. VINBLASTINE. Drugs and targets, record CHEMBL159. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL159

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: VINBLASTINE; ChEMBL
ChEMBL ID: CHEMBL159; ChEMBL
Type: Small molecule; ChEMBL
Other names: NSC-47842, Vinblastina, [3h]-vinblastine; ChEMBL
Other form: VINBLASTINE SULFATE, CHEMBL378544; Drugs and targets
DrugBank: DB00570; DrugBank
InChIKey: JXLYSJRDGCGARV-CFWMRBGOSA-N; ChEMBL
Open Targets' highest stage: Approval, for 1 of its 51 diseases, from ATC; Open Targets

Targets15

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
TUBA1A	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/7846
TUBA1B	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/10376
TUBA1C	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/84790
TUBA3C	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/7278
TUBA3E	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/112714
TUBA4A	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/7277
TUBB	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/203068
TUBB1	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/81027
TUBB2A	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/7280
TUBB2B	Tubulin	Tubulin inhibitor	INHIBITOR	https://conductscience.org/library/genes/347733

1 to 10 of 15Source ChEMBL

See all 15 targets

Diseases51

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
Hodgkins lymphoma	Phase 3	ClinicalTrials.gov	61	61	https://conductscience.org/library/drugs?q=MONDO_0004952
classic Hodgkin lymphoma	Phase 3	ClinicalTrials.gov	24	24	https://conductscience.org/library/drugs?q=MONDO_0009348
low grade glioma	Phase 3	ClinicalTrials.gov	10	10	https://conductscience.org/library/drugs?q=MONDO_0021637
melanoma	Phase 3	ClinicalTrials.gov	9	9	https://conductscience.org/library/drugs?q=MONDO_0005105
non-small cell lung carcinoma	Phase 3	ClinicalTrials.gov	7	7	https://conductscience.org/library/drugs?q=MONDO_0005233
urothelial carcinoma	Phase 3	ClinicalTrials.gov	6	6	https://conductscience.org/library/drugs?q=MONDO_0040679
urinary bladder cancer	Phase 3	ClinicalTrials.gov	5	5	https://conductscience.org/library/drugs?q=MONDO_0001187
bladder transitional cell carcinoma	Phase 3	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=MONDO_0005611
anaplastic large cell lymphoma	Phase 3	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0020325
desmoid tumor	Phase 2	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0007608

1 to 10 of 51Source Open Targets

See all 51 diseases

Trials179

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT01712490	A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma	Phase 3	1,334	2018-11-27	vinblastine	Its name	ClinicalTrials.gov
NCT00003389	Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma	Phase 3	854	2015-09-03	vinblastine	Its name	ClinicalTrials.gov
NCT00005047	4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer	Phase 3	521	2017-06-08	vinblastine	Its name	ClinicalTrials.gov
NCT00006237	S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma	Phase 3	432	2012-09-19	vinblastine	Its name	ClinicalTrials.gov
NCT00145600	Therapy for Pediatric Hodgkin Lymphoma	Phase 2	296	2013-05-07	vinblastine	Its name	ClinicalTrials.gov
NCT00602667	Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma	Phase 2	293	2019-01-30	vinblastine	Its name	ClinicalTrials.gov
NCT00024167	Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer	Phase 3	265	2016-03-22	vinblastine	Its name	ClinicalTrials.gov
NCT03646123	Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma	Phase 2	255	2023-12-21	vinblastine	Its name	ClinicalTrials.gov
NCT02177695	S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer	Phase 2	237	2022-01-03	vinblastine	Its name	ClinicalTrials.gov
NCT03517137	Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study	Phase 2	150	2025-08-11	vinblastine	Its name	ClinicalTrials.gov

1 to 10 of 179

See all 179 trials

Comparisons in its trials38

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
A+AVD vs ABVD: Number of Participants With Abnormal Clinical Laboratory Values	662 of 662	658 of 659	1,321	NCT01712490	Trial comparisons
A+AVD vs ABVD: deaths from any cause	9 of 662	13 of 659	1,321	NCT01712490	Trial comparisons
A+AVD vs ABVD: serious adverse events	284 of 662	178 of 659	1,321	NCT01712490	Trial comparisons
Arm A (ABVD) vs Arm B (Stanford V): serious adverse events	355 of 414	401 of 422	836	NCT00003389	Trial comparisons
Arm A (ABVD) vs Arm B (Stanford V): Incidence of Second Cancers	15 of 395	19 of 399	794	NCT00003389	Trial comparisons
Interferon vs Biochemotherapy: serious adverse events	2 of 193	4 of 185	378	NCT00006237	Trial comparisons
Gemcitabine and Cisplatin vs Dose Dense MVAC: deaths from any cause	28 of 115	25 of 112	227	NCT02177695	Trial comparisons
Gemcitabine and Cisplatin vs Dose Dense MVAC: serious adverse events	1 of 115	4 of 112	227	NCT02177695	Trial comparisons
Standard (APO) With Vincristine (Arm I) vs Consolidation (Includes Vinblastine) (Arm II): serious adverse events	2 of 64	4 of 61	125	NCT00059839	Trial comparisons
ABVD (PET-negative) vs ABVD + BEACOPP + Radiation (PET-positive): Complete Response	73 of 73	16 of 21	94	NCT01118026	Trial comparisons

1 to 10 of 38

See all 38 comparisons in its trials

Papers from its trials169

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40241281	RESULT	1	PubMed
36265483	RESULT	1	PubMed
33507822	RESULT	1	PubMed
32987765	RESULT	1	PubMed
32730187	RESULT	1	PubMed
32661576	RESULT	1	PubMed
32502457	RESULT	1	PubMed
32451316	RESULT	1	PubMed
31708469	RESULT	1	PubMed
31702432	RESULT	1	PubMed

1 to 10 of 169

See all 169 papers from its trials

Tests in its trials1

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome
Verbal Fluency	1	0

Source ConductCognition

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL159

GET https://conductscience.org/api/drugs/v1/CHEMBL159/diseases?page=2

API reference For AI assistants